Key Takeaways on the Treatment of Patients With Relapsed/Refractory MM
The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.
Treatment Decision-Making in Multiple Myeloma
Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.
Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma
The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.
MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies
Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.
Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma
Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.
Dosing Considerations for Bispecific Antibodies in MM
Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.
Recent Data on Bispecific Antibodies in Multiple Myeloma
A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.
Multiple Myeloma Treatment: Patient Profiles
The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.
Treatment Decision-Making in Early-Relapse MM
Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.
Recent Data in the Management of Early-Relapse Multiple Myeloma
A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.
TRiMM-2: Talquetamab + Daratumumab in Relapsed/Refractory Multiple Myeloma
In the context of other clinical trials for patients with relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, review data from TRiMM-2.
Key Takeaways From RedirecTT-1: Teclistamab + Talquetamab in Relapsed/Refractory MM
Expert perspectives on the real-world use of combination teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Relapsed/Refractory MM: Safety and Efficacy Data From RedirecTT-1
Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Relapsed/Refractory Multiple Myeloma: Sequencing BCMA-Targeting Therapies
Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.
Long-Term Followup With Talquetamab in Relapsed/Refractory MM: Infection Rates
Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.
Practical Considerations for Talquetamab Use in Relapsed/Refractory Multiple Myeloma
Following their review of data from MonumenTAL-1, Ajai Chari, MD, and Carolina Schinke, MD, share practical considerations for real-world use of talquetamab in relapsed/refractory multiple myeloma.
Relapsed/Refractory MM: Safety and Efficacy Data From MonumenTAL-1
Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.
MonumenTAL-1 in Relapsed/Refractory MM: Overview of Study Design
Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.
Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
The panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.
Viral Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Robert Mancini, PharmD, explains the viral infections commonly seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.
Clinical Pearls on CRS and ICANS Management in Multiple Myeloma
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.
Patient Case 3: Development of CRS on a Non-BCMA Targeted Bispecific Antibody
Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.
Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma
Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.
Management of ICANS Associated with Bispecific Antibodies in MM
A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.
Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple Myeloma
Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.
Patient Case 2: Development of ICANS on a BCMA-Targeted Bispecific Antibody
Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.
Cytokine Release Syndrome Grading and Management Strategies in MM
Comprehensive insight on the grading system for cytokine release syndrome and available treatment strategies utilized in practice when patients with multiple myeloma develop CRS.